Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesAllergy/Clinical ImmunologyViva Health Xolair concomitant-use Coverage | Open…
    Ask Trek AI about this page
    CurrentViva HealthPolicy IC-P0146

    Xolair® (omalizumab) — Concomitant Therapy Contraindications and Dosing Guidance

    Customize your policy alerts

    Sign up for Viva Health Policy IC-P0146 alerts

    Get alerted when Policy IC-P0146 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Lists agents that are not to be used concomitantly with Xolair (omalizumab) under Viva Health policy IC-P0146; intended for providers seeking coverage/therapy guidance.

    Policy Summary
    PayerViva Health
    PolicyXolair® (omalizumab) — Concomitant Therapy Contraindications and Dosing Guidance
    Policy CodePolicy IC-P0146
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionDocument that the patient is not receiving any agent listed as contraindicated for concomitant therapy with Xolair when submitting prior authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ~100agents listed as not to be used concomitantly
    ~40distinct drug names listed
    multiplepediatric dosing table fragments
    J2357HCPCS code included

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    16ICD-10 codes listed

    Coverage Criteria — Concomitant Therapy Contraindications & Dosing

    Dosing and administration — covered when tables applied

    Covered when ALL of the following indication-specific dosing rules are met; dose and frequency are determined by pre-treatment total serum IgE and body weight unless a fixed dose is specified.

    Moderate to severe persistent asthma: Administer 75 to 375 mg subcutaneously every 2 or 4 weeks. Determine specific dose and dosing frequency using the member's pre-treatment total serum IgE (IU/mL) and body weight (kg) per the policy tables.IgE and weight table

    See dosing tables in policy (chunks 79, 81).

    Chronic spontaneous urticaria: Administer 150 mg or 300 mg subcutaneously every 4 weeks. Dosing for this indication is fixed and is not based on serum IgE or body weight.fixed doses

    (chunk 78)

    Chronic rhinosinusitis with nasal polyps: Administer 75 to 600 mg subcutaneously every 2 or 4 weeks. Determine specific dose and dosing frequency using the member's pre-treatment total serum IgE (IU/mL) and body weight (kg) per the policy tables.IgE and weight table

    (chunk 78)

    IgE-mediated food allergy: Administer 75 to 600 mg subcutaneously every 2 or 4 weeks. Determine specific dose and dosing frequency using the member's pre-treatment total serum IgE (IU/mL) and body weight (kg) per the policy tables.IgE and weight table

    (chunks 78, 79, 81-82)

    General dosing requirement: Pre-treatment total serum IgE (IU/mL) and body weight (kg) must be measured and documented to select dose and dosing frequency where the table-based method applies.document IgE and weight

    (chunks 78, 79)

    Pediatric initial dosing (ages 6 to <12)

    Pediatric initial dosing is covered when the dose and frequency exactly match the policy's pediatric pre-dosing body weight and IgE-based table for children who begin therapy between ages 6 and <12.

    Pediatric dosing table match: For children who begin omalizumab at ages 6 to <12 years, administer the mg dose and dosing frequency specified in the pediatric pre-dosing IgE (IU/mL) by body weight (kg) tables in the policy. Follow the table entries for the applicable pre-treatment IgE range and body weight band; some cells are labeled 'Do Not Dose' or left blank and those combinations are not supported by the table.per pediatric table

    See pediatric tables spanning chunks 81 and 90–102; frequency is every 2 or 4 weeks as shown in the table and some high IgE/weight cells are 'Do Not Dose'.

    Handling of out-of-table entries: Do not dose for pre-dosing body weight/IgE combinations explicitly labeled 'Do Not Dose' or represented by blank cells in the pediatric tables; requests for dosing outside the table may be denied.Do Not Dose / blank cells

    (chunks 101, 102)

    Concomitant use of the agents listed in chunks 18–37 is explicitly designated as contraindicated with Xolair (omalizumab). Prior authorization and clinical review must confirm the member is not receiving any agent named in the 'Agents NOT to be used Concomitantly' list before approving Xolair.

    Examples of specific agents listed as contraindicated for concomitant use with Xolair include ustekinumab (Stelara / Starjemza / Steqeyma / Wezlana and biosimilar/brand variants), ixekizumab (Taltz), tezepelumab (Tezspire), golimumab (Simponi ARIA), risankizumab (Skyrizi), deucravacitinib (Sotyktu), spesolimab (Spevigo), and other biologic agents listed in the policy.

    Concurrent use is not permitted for several targeted and small-molecule agents; examples repeated in the policy include tofacitinib (Xeljanz / Xeljanz XR), various tocilizumab products (Tofidence / Tyenne / equivalents), guselkumab (Tremfya), rituximab products (Truxima / Riabni / Rituxan), and natalizumab products (Tysabri / Tyruko). Requests asserting concomitant administration with these agents should be reviewed and are likely to be denied.

    The policy contains an overarching list that includes multiple biologics and JAK inhibitors designated as contraindicated for concomitant therapy with Xolair (omalizumab). This covers a broad range of drug classes (e.g., anti‑IL, anti‑TNF, anti‑CD20, JAK inhibitors) and specific brand/generic entries named across the document.

    The dosing tables supplied in the policy include explicit 'Do Not Dose' entries for some pre-treatment body weight/total serum IgE combinations and contain blank cells for other high weight/IgE ranges where dosing is not provided. When the tables do not prescribe a dose, dosing is not supported by the policy.

    Medicare coverage determinations are governed by CMS policy; the policy notes that the preceding information applies to non‑Medicare coverage and that Medicare Part B coverage is subject to the Medicare Benefit Policy Manual, applicable National Coverage Determinations (NCDs), Local Coverage Determinations (LCDs), and Local Coverage Articles (LCAs).

    Repeated policy language explicitly designates the listed products as contraindicated for concomitant use with Xolair (omalizumab). This redundant clause reinforces that any named agent in the 'Agents NOT to be used Concomitantly' list should not be administered at the same time as omalizumab.

    Several pediatric pre‑treatment body weight and serum total IgE combinations are labeled as 'Do Not Dose' in the pediatric dosing tables for children beginning omalizumab between ages 6 to <12 years; other table cells are left blank where dosing guidance is not provided.

    Dosing requests that fall into combinations explicitly labeled 'Do Not Dose' or that require doses for weight/IgE cells left blank in the table are not supported by the policy's dosing tables and may be denied as not medically necessary or unsupported dosing.

    Coding — HCPCS, NDC, ICD-10, and Dosing Parameters

    Codes referencedmixed
    N/ANo explicit CPT/HCPCS/ICD-10/NDC codes provided in this section.
    Covered HCPCS CodesHCPCSCovered
    J2357Injection, omalizumab, 5 mg; 1 billable unit = 5 mg
    Listed NDCsNDC
    50242-0214-xxXolair 75 mg single-dose prefilled syringe or autoinjector
    50242-0215-xxXolair 150 mg single-dose prefilled syringe or autoinjector
    50242-0040-xxXolair 150 mg single-dose vial powder for injection
    50242-0227-xxXolair 300 mg single-dose prefilled syringe or autoinjector
    Covered ICD-10 Diagnosis CodesICD-10Covered
    J33.0Polyp of nasal cavity
    J33.1Polypoid sinus degeneration
    J33.8Other polyp of sinus
    J33.9Nasal polyp, unspecified
    J45.40Moderate persistent asthma, uncomplicated
    J45.50Severe persistent asthma, uncomplicated
    L29.89Other pruritus
    L29.9Pruritus, unspecified
    L50.0Allergic urticaria
    L50.1Idiopathic urticaria
    1–10 of 21
    1/3
    Referenced CMS Local Coverage Articlemixed
    A52448Local Coverage Article: Billing and Coding: Omalizumab and biosimilar, OMLYCLO® (omalizumab-igec)
    Pre-treatment total serum IgE ranges used to determine dosing
    Pre-treatment total serum IgE ranges used in tablesMultiple discrete bands are used (examples shown in policy: 30–60; >60–70; >70–90; >90–150; ≥30–100; >100–200; >200–300).
    Highest IgE bands referencedTables include bands described as >200–300 and references to further table sections for values above these ranges.
    Purpose of IgE measurementSerum total IgE (IU/mL) measured before the start of treatment is used with body weight to determine omalizumab dose and frequency.
    Dosing frequency threshold — frequency specified as every 2 or 4 weeks in tables
    Dosing frequency options in tablesDose tables specify administration every 2 weeks or every 4 weeks depending on indication and weight/IgE band.

    Provider Actions — Prior Authorization, Documentation, and Billing

    Prior Authorization

    PA: Check for listed contraindicated concomitant agents

    Prior authorization reviewers must verify whether the member is receiving any agents listed as “Agents NOT to be used Concomitantly”; the PA decision must consider those agents when adjudicating a request for Xolair (omalizumab).

    • PA must flag concomitant use of any agent in the policy's “Agents NOT to be used Concomitantly” list.
    Prior Authorization

    PA: Account for explicitly named contraindicated agents

    Prior authorization review must account for the specific agents named in the policy as explicitly contraindicated as concomitant therapy (for example: ustekinumab/Stelara/Steqeyma/Wezlana variants, ixekizumab/Taltz, tezepelumab/Tezspire, golimumab/Simponi ARIA, risankizumab/Skyrizi, deucravacitinib/Sotyktu, tofacitinib/Xeljanz, tocilizumab/Tofidence/Tyenne, rituximab/Truxima, guselkumab/Tremfya, natalizumab/Tysabri/Tyruko, etrasimod/Velsipity, and others listed).

    • Include named biologics, JAK inhibitors, and other listed products when checking for contraindicated concomitant therapy.

    Background — Policy Purpose and Scope

    Background: this policy section enumerates approximately one hundred individual products across biologic, targeted, and small‑molecule classes that the plan designates as not to be used concomitantly with Xolair (omalizumab). The list includes, by class, anti‑IL agents (e.g., ustekinumab, ixekizumab), anti‑TNF agents (e.g., infliximab), anti‑CD20 agents (e.g., rituximab), and multiple JAK inhibitors (e.g., tofacitinib), among many others.

    Definitions and Key Terms

    Contraindicated as Concomitant Therapy — designation that agents should not be administered concurrently with Xolair
    Definition — Contraindicated as Concomitant TherapyThe policy repeatedly designates certain agents as 'Contraindicated as Concomitant Therapy', meaning they should not be administered at the same time as Xolair (omalizumab).
    Scope of designationThis phrasing is used throughout the 'Agents NOT to be used Concomitantly' lists to mark products across multiple classes (biologics, JAK inhibitors, targeted agents).
    Implication for prior authorizationConcomitant use of any agent labeled 'Contraindicated as Concomitant Therapy' may trigger denial of coverage for concurrent administration with Xolair.
    Contraindicated as Concomitant Therapy — drugs explicitly listed that should not be administered concurrently with Xolair
    Examples of explicitly listed contraindicated drugs (selection)Ustekinumab (Stelara/Steqeyma/Starjemza), Ixekizumab (Taltz), Tezepelumab (Tezspire), Golimumab (Simponi ARIA), Risankizumab (Skyrizi), Deucravacitinib (Sotyktu), Spesolimab (Spevigo), Tofacitinib (Xeljanz), Tocilizumab (Tofidence/Tyenne), Rituximab (Truxima), Guselkumab (Tremfya), Natalizumab (Tysabri/Tyruko), Etrasimod (Velsipity).
    Policy Summary
    PayerViva Health
    PolicyXolair® (omalizumab) — Concomitant Therapy Contraindications and Dosing Guidance
    Policy CodePolicy IC-P0146
    Change TypeNo material changes
    Effective DateJul 1, 2026
    Last ReviewJul 1, 2026
    Next Review DateJul 1, 2026
    Key ActionDocument that the patient is not receiving any agent listed as contraindicated for concomitant therapy with Xolair when submitting prior authorization.
    SourceLink
    On This Page
    Coverage Criteria — Concomitant Therapy Contraindications & DosingCoding — HCPCS, NDC, ICD-10, and Dosing ParametersProvider Actions — Prior Authorization, Documentation, and BillingBackground — Policy Purpose and ScopeDefinitions and Key Terms
    Frequency documentation: Document whether the table-specified frequency is every 2 weeks or every 4 weeks as indicated for the selected weight/IgE band when submitting for coverage/prior authorization.frequency = 2 or 4 weeks

    (chunks 81, 90, 101)

    Pediatric tables frequencyPediatric dosing tables for ages 6 to <12 present doses to be administered every 2 or 4 weeks; some cells indicate a 2‑week frequency.
    Indication-specific frequency noteChronic spontaneous urticaria dosing is fixed every 4 weeks; asthma, chronic rhinosinusitis with nasal polyps, and food allergy use 2- or 4-week schedules determined by tables.
    Prior Authorization

    Concomitant therapy check required at PA

    At prior authorization, confirm the requested Xolair will not be given together with any product designated in the policy as “Agents NOT to be used Concomitantly” or labeled “Contraindicated as Concomitant Therapy.”

    • If the member is receiving any listed agent, PA should not approve concomitant administration per the policy designation.
    Documentation Required

    PA must include pre-treatment IgE and body weight for dosing/frequency

    Document pre-treatment total serum IgE (IU/mL) and current body weight (kg) with the PA request, since dose (mg) and dosing frequency (every 2 or 4 weeks) are determined by those baseline values.

    • Include measured pre-treatment total serum IgE (IU/mL).
    • Include current body weight (kg).
    • State the dose and proposed frequency tied to the IgE/weight table.
    Prior Authorization

    PA: Follow pediatric weight/IgE dosing table for ages 6 to <12

    For children who begin omalizumab at ages 6 to <12, prior authorization must reference and match the pediatric pre-dosing body weight and IgE-based dosing tables (including specified mg doses and frequency every 2 or 4 weeks and any ‘Do Not Dose’ designations in the table).

    • PA dosing must align to the pediatric weight/IgE tables provided in the policy.
    • Do Not Dose or blank table cells indicate dosing is not supported for that combination and should be reflected in the PA decision.
    Prior Authorization

    PA must be tied to covered diagnoses and PA rationale

    Prior authorization determinations are guided by clinical indication, safety/efficacy, and cost considerations; ensure the submitted diagnosis matches a covered ICD‑10 diagnosis listed in Appendix 1 when applicable.

    • Confirm the indicated ICD‑10 code corresponds to the policy's covered diagnoses in Appendix 1 (e.g., J45.40, J45.50, J33.x, L50.x, Z91.0x, etc.).
    • Apply PA criteria considering indication, safety/efficacy, and cost per the NQTL assessment.
    Step Therapy

    Step therapy: none specified in this section

    No step therapy requirements are specified in this segment; the policy section lists agents contraindicated for concomitant use but does not impose step therapy sequencing for Xolair.

    • Do not require prior failure of other listed agents as a step-therapy condition — none is specified here.
    Step Therapy

    Step therapy not provided (no step therapy guidance)

    This policy segment contains no step therapy guidance; reviewers should not apply step-therapy controls based on this concomitant-use list alone.

    • Focus PA review on contraindicated concomitant agents and dosing rules rather than step therapy sequencing.
    Step Therapy

    Step therapy: not specified

    No step therapy requirements are stated in these chunks; the content is limited to products that must not be used concomitantly with Xolair.

    • Step therapy controls are not defined in this document segment.
    Note

    NQTL considerations: PA design informed by NQTL checklist

    The policy's NQTL checklist documents that PA was applied after considering factors such as indication, safety/efficacy, and drug cost; reviewers should follow the PA processes informed by that NQTL assessment.

    • Indication = consider for PA; Safety and efficacy = consider for PA; Cost = consider for PA (Appendix A).
    Note

    Utilization management application per NQTL checklist

    Utilization management (including prior authorization) was applied across benefits per the NQTL checklist; apply utilization management consistently when adjudicating Xolair requests.

    • The NQTL checklist indicates utilization management methods (eg, PA) were considered and applied comparably across MH/SUD and M/S drug benefits.
    Documentation Required

    Document absence of contraindicated concomitant agents for PA

    Include clinical documentation that the member is not receiving any agent listed in the policy’s “Agents NOT to be used Concomitantly” when submitting a PA; the policy requires documentation demonstrating absence of the contraindicated agents.

    • Explicitly state in the chart/PA submission that the member is not on any listed biologic, JAK inhibitor, or other named product.
    • Supply medication history or attestations showing absence of listed agents.
    Documentation Required

    PA documentation must show member is not on contraindicated agents

    Clinical documentation submitted with the PA must demonstrate the member is not receiving any listed contraindicated agents (the policy lists numerous biologics and immunomodulators that are contra‑indicated as concomitant therapy).

    • Provide med list, recent clinic notes, or pharmacy fill history showing the member is not on the listed agents.
    Documentation Required

    Document absence of contraindicated concomitant therapy

    When requesting Xolair, ensure documentation specifically reflects that the patient is not receiving any agent designated as “Contraindicated as Concomitant Therapy” in the policy.

    • Document absence of tofacitinib/Xeljanz, ustekinumab/Stelara variants, natalizumab/Tysabri, rituximab/Truxima, and other listed products as applicable.
    Documentation Required

    Require baseline IgE and body weight for dosing

    Obtain and include pre-treatment total serum IgE (IU/mL) and body weight (kg) with the PA request because these baseline labs are required to determine dose and dosing frequency per the policy tables.

    • Pre-treatment total serum IgE (IU/mL) must be measured before start of treatment.
    • Body weight (kg) must be provided to select the appropriate dose/frequency from the tables.
    Billing Rule

    Billing: use HCPCS J2357 and include NDC

    Submit billing using HCPCS code J2357 (injection, omalizumab, 5 mg — 1 billable unit = 5 mg) and include the appropriate Xolair NDC when applicable (policy provides NDC examples for 75 mg, 150 mg, and 300 mg presentations).

    • Bill units of J2357 corresponding to total mg administered (1 unit = 5 mg).
    • Include NDC from the policy (eg, 50242-0214-xx; 50242-0215-xx; 50242-0040-xx; 50242-0227-xx) when required for product identification.
    Documentation Required

    Medicare members: follow NCDs/LCDs/LCAs and CMS guidance

    For Medicare members, follow applicable Medicare policies (Medicare Benefit Policy Manual, NCDs/LCDs/LCAs) and any referenced local coverage articles when making coverage and documentation decisions for outpatient Part B claims.

    • Medicare NCDs/LCDs/LCAs apply and must be followed where relevant; the policy's preceding information is intended for non‑Medicare determinations.
    Denial Risk

    Denial risk: concomitant use may trigger denial

    Use of any agent listed in the policy's “Agents NOT to be used Concomitantly” with Xolair may lead to denial of the request; prior authorization reviewers should consider concomitant use a denial risk per the policy.

    • If documentation shows concurrent use of a listed agent, PA may be denied because concomitant therapy is designated contraindicated.
    Denial Risk

    Concomitant use designated contraindicated — denial basis

    The policy designates concomitant use of the listed agents with Xolair as contraindicated; requests that propose co-administration with those agents can be a basis for denial of authorization.

    • Concomitant biologics, JAK inhibitors, and other named immunomodulators are listed as contraindicated and may prompt denial if present.
    Denial Risk

    Denial risk: listed agents flagged as contraindicated

    The policy repeatedly specifies that listed agents are “Contraindicated as Concomitant Therapy”; use of any of those agents with Xolair is a denial risk and should be documented and reviewed accordingly.

    • Review medication history for any agents labeled “Contraindicated as Concomitant Therapy” (eg, tofacitinib/Xeljanz, ustekinumab variants, natalizumab, tocilizumab, guselkumab, rituximab).
    Denial Risk

    Concomitant therapy contraindications can lead to denial

    Requests that involve concomitant use of agents listed in the policy may be denied; reviewers should treat proposed co‑administration with the listed biologics/JAK inhibitors/targeted agents as contraindicated and document the rationale for denial if applicable.

    • If member is on a listed product, document the contraindication and basis for denial per the policy.
    Denial Risk

    Out‑of‑table dosing (Do Not Dose/blank cells) may be denied

    If a requested dose/frequency is outside the policy’s dosing tables — including combinations labeled “Do Not Dose” or blank cells in the pediatric tables — the request may be denied for lack of table-supported dosing.

    • Table cells labeled “Do Not Dose” or left blank indicate dosing is not supported and may result in billing or clinical denial for out‑of‑table dosing requests.
    Prior Authorization

    PA rationale: consider indication, safety/efficacy, and cost

    Prior authorization may be applied based on clinical indication, safety/efficacy, and cost considerations as documented in the policy; reviewers should apply PA consistent with those rationales.

    • Apply PA where indication, safety/efficacy, or cost considerations were identified as reasons to consider PA in the NQTL checklist.
    Classes representedListed agents span monoclonal antibodies, biosimilars, JAK inhibitors, and other targeted immunomodulators.
    Repetition across listThe policy repeats many product names and brand/generic variants across multiple chunks to enumerate contraindicated agents comprehensively.
    Contraindicated as Concomitant Therapy — explicit policy designation phrasing repeated in document
    Policy phrasing used verbatimThe document repeatedly states: 'Contraindicated as Concomitant Therapy = [product name]'.
    Effect of phrasingThis explicit designation is applied to each named product to indicate it should not be used concurrently with Xolair.
    Placement in policyThe phrasing appears throughout the 'Agents NOT to be used Concomitantly' section to mark contraindications consistently.
    Pre-treatment serum total IgE — definition and role in dosing determination
    Definition of pre-treatment serum total IgESerum total immunoglobulin E measured before treatment (IU/mL) used with body weight (kg) to determine omalizumab dose and dosing frequency.
    Clinical roleRequired baseline lab: pre-treatment total serum IgE must be determined to select dose and dosing frequency for asthma, chronic rhinosinusitis with nasal polyps, and IgE‑mediated food allergy.
    Not used for certain indicationsChronic spontaneous urticaria dosing is not dependent on serum total IgE or body weight.
    HCPCS J2357 — definition (Injection, omalizumab, 5 mg; 1 unit = 5 mg)
    HCPCS code descriptionJ2357 — Injection, omalizumab, 5 mg; 1 billable unit = 5 mg.
    Billing unitCharge and billing use units where 1 unit equals 5 mg of omalizumab.
    Use in documentationPolicy instructs submitting J2357 units and including NDC when applicable for product identification.
    NDC examples — listed NDCs for available Xolair presentations
    Xolair 75 mg prefilled syringe/autoinjector NDC50242-0214-xx
    Xolair 150 mg prefilled syringe/autoinjector NDC50242-0215-xx
    Xolair 150 mg single-dose vial powder NDC50242-0040-xx
    Xolair 300 mg prefilled syringe/autoinjector NDC50242-0227-xx